Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

The aim of this study was to evaluate the effects of Sacubitril/Valsartan (S/V) on clinical,
laboratory and echocardiographic parameters and outcomes in a real-world population with …

Abstract Introduction Sacubitril/valsartan (S–V) has been shown to reduce clinical outcomes
in patients with heart failure with reduced ejection fraction (HFrEF). This benefit has been …

Aim Sacubitril valsartan (SV) has revolutionized disease history in patients with heart failure
and reduced ejection fraction (HFrEF). Our study assessed SV impact on clinical and …

Objective: We evaluated the clinical efficacy of sacubitril/valsartan in a group of ambulatory
patients with heart failure (HF) with reduced ejection fraction (HFrEF) referred to our HF …

Background Sacubitril/valsartan has been shown to improve mortality and reduce
hospitalizations in patients with heart failure (HF) with reduced ejection fraction (HFrEF) …

Background Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure
with reduced ejection fraction (HFrEF) are often not reached in clinical practice. Objectives …

Purpose Sacubitril/valsartan has been demonstrated to improve prognosis and outcomes in
heart failure with reduced ejection fraction (HFrEF) patients. We sought to compare the …

Aims ARIADNE aimed to assess the association between effects of sacubitril/valsartan and
no sacubitril/valsartan treatment and clinical characteristics, functional capacity, and clinical …

Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …